harvard pilgrim glp 1 coverage Point32Health, Blue Cross reach profitability after GLP-1 losses Why Blue Cross Blue Shield

GLP-1 receptor agonists should be considered in patients with type II diabetes and high ASCVD risk OR patients without diabetes who are overweight/obese and have a history of cardiovascular disease

It took decades of pharmaceutical research and billions of dollars in development

same active ingredients, different formulations and packaging All injectable GLP-1 medications are biologics large-molecule proteins that are more sensitive to temperature, light, and physical degradation than small-molecule oral medications

Telling us about your GLP-1 medication does not make you difficultit makes you a well-informed partner in your own safety

Cannot redeclare control with same name "grid_4_overlay_background_repeat"

10.1159/000540654 57 HuangM.ChenH.WangH.ZhangY.LiL.LanY.et al (2025)